This review summarizes the pharmacology and clinical data for edoxaban as an alternative to vitamin K antagonists for the management of atrial fibrillation and venous thromboembolism.
Answers are grounded in this paper and cite their sources.
Edoxaban remains a VKA alternative in AF and VTE; leaves open need for updated outcome trials.
Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed onset and offset. Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in patients requiring chronic anticoagulation. This review examines the pharmacology and clinical data of edoxaban as a therapeutic alternative.
No takes yet. Share an insight, caveat, or question.
Stacy et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: